ARTICLE | Clinical News
Uptravi selexipag regulatory update
January 4, 2016 8:00 AM UTC
FDA approved an NDA from Actelion for Uptravi selexipag to treat pulmonary arterial hypertension (PAH). Actelion plans to launch the long-acting prostacyclin (IP) receptor ( PGI2; PTGIR) agonist ear...